Cargando…
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen receptor (AR) plays an important role in the progression of prostate cancer and has been targeted by castration or AR-antagonists. The emergence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) is inevitable. However, it is not entirely clear how ADT f...
Autores principales: | Chen, Xuanrong, Shao, Yi, Wei, Wanqing, Zhu, Shimiao, Li, Yang, Chen, Yutong, Li, Hanling, Tian, Hao, Sun, Guijiang, Niu, Yuanjie, Shang, Zhiqun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637107/ https://www.ncbi.nlm.nih.gov/pubmed/36335093 http://dx.doi.org/10.1038/s41419-022-05366-8 |
Ejemplares similares
-
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2023) -
Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
por: Li, Yang, et al.
Publicado: (2023) -
AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2015) -
AB187. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2016) -
Increased expression of CELSR3 indicates a poor prognostic factor for Prostate Cancer
por: Chen, Xuanrong, et al.
Publicado: (2021)